Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612123 | 1.00 | CAPN1 (0.63) | CAPN1P2RX7HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL28820300 | 0.91 | CAPN1 (0.64) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL289574 | 0.91 | P2RX7 (0.56) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL288652 | 0.91 | P2RX7 (0.56) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL288651 | 0.91 | P2RX7 (0.56) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL24434877 | 0.87 | CAPN1 (0.51) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL28681218 | 0.86 | CAPN1 (0.58) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL22452838 | 0.86 | CAPN1 (0.58) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL5741011 | 0.82 | KMT2A (0.54) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL1162612 | 0.82 | P2RX7 (0.54) | CAPN1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941468-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| CN-102482212-B | Carboxamide compounds and they are as the purposes of calpain inhibitor | ABBVIE (US) | 2015-08-26 | — | — | CN | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008116845-A1 | PIPERIDINONE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-1537089-A4 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080021050-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7211580-B2 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1537089-A2 | COMPOUNDS COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040142949-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004009036-A2 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | CAPN1 2481/4885P2RX7 4829/4885HCRTR1 4523/4885 |
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | CAPN1 4105/4885P2RX7 3305/4885HCRTR1 1200/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | CAPN1 3710/4885P2RX7 450/4885HCRTR1 4385/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885P2RX7 1852/4885HCRTR1 169/4885 |
| US-20040142949-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | CAPN1 2481/4885P2RX7 4829/4885HCRTR1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.